Last reviewed · How we verify
Sham Bimatoprost SR
Sham Bimatoprost SR is a prostaglandin analog that mimics the action of prostaglandin F2-alpha.
Sham Bimatoprost SR is a prostaglandin analog that mimics the action of prostaglandin F2-alpha. Used for Treatment of glaucoma and ocular hypertension.
At a glance
| Generic name | Sham Bimatoprost SR |
|---|---|
| Sponsor | AbbVie |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Prostaglandin analogs like Sham Bimatoprost SR work by binding to and activating the prostaglandin receptor, leading to increased outflow of aqueous humor from the eye and reduced intraocular pressure. This mechanism is similar to that of other prostaglandin analogs, such as bimatoprost, which is used to treat glaucoma and ocular hypertension.
Approved indications
- Treatment of glaucoma and ocular hypertension
Common side effects
- Eyelash growth
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham Bimatoprost SR CI brief — competitive landscape report
- Sham Bimatoprost SR updates RSS · CI watch RSS
- AbbVie portfolio CI